ArticleInfection and drug resistance2025
Epidemiology and Antimicrobial Resistance Trends of Bloodstream Infections During and After the Implementation of the National Action Plan on Antimicrobial Resistance in Mwanza, Tanzania: A Comparative Cross-Sectional Study.
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Genomic characterization of clinical isolates of carbapenem-resistantJAC-antimicrobial resistance · 2026Article
- Genomic epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Mwanza, Tanzania.Journal of global antimicrobial resistance · 2026Article
- Whole-genome sequencing of clinical methicillin-resistant Staphylococcus aureus isolates across hospitals in Mwanza, Tanzania.Access microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Purpose: Bloodstream infections (BSIs) caused by antimicrobial-resistant pathogens, especially WHO-Bacterial-Priority-Pathogens (WHO-BPPs), contribute to significant mortality. The current study determined the prevalence of BSIs, causative bacterial pathogens and their antimicrobial susceptibility profiles, and factors associated with laboratory-confirmed BSIs by WHO-BPPs during and after National Action Plan on Antimicrobial Resistance (NAP-AMR) implementation in Mwanza, Tanzania. Patients and Methods: A comparative cross-sectional study was conducted among sepsis patients in District, Regional, and Zonal Referral Hospitals from June 2019 to June 2020 (during NAP-AMR) and March to July 2023 (after NAP-AMR). Blood cultures were processed using conventional methods, while bacterial identification and antimicrobial susceptibility testing were performed using Vitek MS (MALDI-TOF-MS) and Vitek 2, respectively. STATA version 15.0 was used for data analysis. Results: Among 1842 enrolled patients (median age: 5 years, IQR: 0-31), 51.4% were female. The overall prevalence of BSIs was 14.7% (271/1842). A total of 306 bacterial isolates were identified, with Gram-negative bacteria predominating during (92.4%) and after (73.5%) NAP-AMR. Conclusion: We observed a high prevalence of BSIs with a rising proportion of BSIs caused by WHO-BPPs, particularly in higher-tier hospitals and after the implementation of NAP-AMR. Our findings highlight the need of hospital-specific antibiograms and reinforced infection prevention measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.